New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients without prior heart attack or stroke and showed significant benefits regardless of concurrent diabetes therapies. These findings highlight the importance of aggressive LDL-C management in high-risk diabetes to prevent heart attacks and strokes. Amgen also presented real-world evidence emphasizing the need for sustained treatment adherence in obesity and diabetes care to maximize therapy benefits.
The Schwab U.S. Dividend Equity ETF (SCHD) focuses on 100 stocks with strong dividend histories, offering retirees a reliable income with a 3.27% yield and low fees. However, its top 10 holdings make up 41% of the fund, exposing investors to higher s...
Amgen Inc. has been upgraded to a cautious Buy due to its improved fundamentals, diversified drug pipeline, and attractive risk/reward profile despite recent underperformance against the S&P 500. Key growth drivers include drugs like Imdelltra, Upliz...
Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, featuring executives Peter Griffith and Murdo Gordon. The presentation will be webcast live and accessible to the public, investors, and me...
Quantinuum, formed by merging Honeywell's quantum division and Cambridge Quantum, debuted on Nasdaq at $68 per share, raising $1.68 billion in an upsized IPO. The company, valued at about $17.6 billion, offers full-stack quantum computing hardware an...
The European Commission has approved Amgen's IMDYLLTRA (tarlatamab) as a monotherapy for adults with advanced small-cell lung cancer (SCLC) after progression on platinum-based chemotherapy. This approval is based on the Phase 3 DeLLphi-304 trial show...
